Technical Analysis for ATHX - Athersys, Inc.
|Grade||Last Price||% Change||Price Change|
ATHX closed up 1.42 percent on Friday, January 18, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical ATHX trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Bullish Engulfing||Bullish||0.00%|
|Jan 18||Outside Day||Range Expansion||0.00%|
|Jan 18||Oversold Stochastic||Weakness||0.00%|
|Jan 17||New Downtrend||Bearish||1.42%|
|Jan 17||Narrow Range Bar||Range Contraction||1.42%|
|Jan 17||Inside Day||Range Contraction||1.42%|
|Jan 17||Oversold Stochastic||Weakness||1.42%|
|Jan 16||Stochastic Reached Oversold||Weakness||1.42%|
|Jan 16||Oversold Stochastic||Weakness||1.42%|
|Jan 14||Narrow Range Bar||Range Contraction||0.70%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ATHX news...
|52 Week High||3.09|
|52 Week Low||1.29|
|200-Day Moving Average||1.993|
|50-Day Moving Average||1.734|
|20-Day Moving Average||1.4775|
|10-Day Moving Average||1.486|
|Average True Range||0.0925|
|Chandelier Exit (Long, 3 ATRs )||1.5125|
|Chandelier Exit (Short, 3 ATRs )||1.6375|
|Upper Bollinger Band||1.6134|
|Lower Bollinger Band||1.3416|
|Percent B (%b)||0.33|
|MACD Signal Line||-0.0925|
|Market Cap||162.89 Million|
|Num Shares||114 Million|
|Price-to-Earnings (P/E) Ratio||-5.50|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||1.54|
|Resistance 3 (R3)||1.53||1.49||1.52|
|Resistance 2 (R2)||1.49||1.46||1.49||1.51|
|Resistance 1 (R1)||1.46||1.45||1.48||1.47||1.51|
|Support 1 (S1)||1.39||1.39||1.41||1.40||1.35|
|Support 2 (S2)||1.35||1.38||1.35||1.35|
|Support 3 (S3)||1.32||1.35||1.34|
|Support 4 (S4)||1.33|